REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – Oral cladribine appears to be effective in reducing relapse rates and disability progression, according to the preliminary results from the phase III CLARITY (Cladribine tablets treating MS orally) trial (Giovannoni et al. AAN 2009; abstract LBS.001).